Information Provided By: 
Fly News Breaks for May 11, 2016
JAZZ
May 11, 2016 | 06:34 EDT
Piper Jaffray analyst David Amsellem says the valuation of Jazz Pharmaceuticals remains attractive following the company's Q1 results. JAZZ continues to add Xyrem patients "at a steady clip" while the patent settlements announced last night bring greater visibility on durability, Amsellem tells investors in a research note. He reiterates an Overweight rating on the shares with a $186 price target. Mizuho this morning upgraded Jazz to Buy.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
